A Radnor biopharmaceutical company has been awarded $720,000 to fund an experimental therapy being developed there for amyotrophic lateral sclerosis (ALS), writes John George for Philadelphia Business Journal.

Aclipse Therapeutics of Radnor received the grant from Austrailia’s largest independent funder of ALS, FightMND, based in Melbourne.

ALS is a progressive neurodegenerative disease  affecting muscle movement as it attacks nerve cells in the brain and spinal cord.

About 5,600 people in the US are diagnosed with ALS each year. Up to 20,000 Americans have the disease at any given time.

There is no cure or long-term effective therapies for ALS.

Aclipse’s experimental therapy, M102, has shown in pre-clinical trials, the potential to slow or stop the progression of the disease by activating two signaling pathways researchers believe are important ALS pathways.

“The FightMND award confirms M102’s success to date, and validates M102’s potential for a precision medicine approach for the treatment of ALS,” said Raymond K. Houck, CEO of Aclipse.

The grant will support development of M102 into human clinical studies.

Dr. Bec Sheean, research director at FightMND, said M102 could provide a disease-modifying drug that would improve on current treatments.

Read more about Aclipse Therapeutics of Radnor here.

You Might Also Like                            

Radnor Pharma Company Gets Head Start on Treating Fragile X in Children

Radnor’s L.E.A.F. Pharmaceuticals Establishes Subsidiary in Rwanda

Radnor’s Marinus Pharmaceuticals Aims to Generate $35 Million from Public Stock Offering